This secondary activation is particularly decisive also in AML, where NFκB drives clonogenicity and drug resistance, regardless of whether the downstream pathway is KMT2A-lysine methyltransferase 2A (MLL)-dependent or homeobox (HOXA)-dependent [63]. The gene discussed is NFKB1; the disease is acute myeloid leukemia.